Ibex Prostate

Ibex Prostate is a clinical-grade, AI-powered pathology solution designed to assist pathologists in the detection and grading of prostate cancer. Prostate cancer is among the most common malignant diseases in men worldwide, with more than one million new cases diagnosed each year, and accurate, timely diagnosis is critical for guiding treatment decisions and improving survival rates. Ibex Prostate addresses the core challenges of prostate biopsy analysis — including increasing case volumes, subjectivity in Gleason grading, small tumor sizes, and large numbers of tissue cores per case — by providing intelligent, automated support throughout the diagnostic workflow.

Deployed in multiple digital pathology workflows and used by pathologists in everyday clinical practice at leading health systems and diagnostic providers worldwide, Ibex Prostate delivers clinical-grade accuracy alongside meaningful gains in productivity and turnaround time.

Key Capabilities and Diagnostic Tools

• Case prioritization worklist to help pathologists focus on the most urgent cases first
• Integrated slide viewer for seamless digital review
• AI-driven cancer heatmaps, including Gleason heatmaps and perineural invasion heatmaps
• Automated Gleason grading to reduce subjectivity and inter-observer variability
• Tumor measurements and identification of non-cancer findings
• IHC (immunohistochemistry) preordering support
• AI-driven reporting to streamline documentation and reduce manual effort
• 100% quality control across all cases to reduce diagnostic errors

Clinically Proven Performance

• Outstanding outcomes demonstrated in rigorous clinical studies conducted at multiple institutes across the world, performed in different workflows and on various scanning systems and staining platforms
• Cancer detection accuracy: AUC of 0.99, sensitivity of 98.4%, and specificity of 97.3%
• In AI versus microscope primary diagnosis studies: a 37% productivity gain and a 27% reduction in diagnosis time were observed
• Significantly lower rate of diagnostic discrepancy with AI-assisted review (4.84%) compared to microscope-only review (7.13%)
• Clinical findings published in The Lancet Digital Health and presented at USCAP and the European Congress of Pathology

Real-World Deployments

• Live deployment at CorePlus in Puerto Rico, demonstrating integration into routine clinical practice
• Roll-out at the Betsi Cadwaladr University Health Board in Wales, highlighting adoption within national health systems
• Prospective reader studies confirming clinical-level accuracy in primary diagnosis and reporting of prostate biopsies in routine use

Ibex Prostate is CE marked under IVDD and also CE marked under IVDR for Ibex First Read for prostate. It is registered with the UK MHRA and with ANVISA in Brazil. In the United States, Ibex Prostate is available for Research Use Only (RUO) and has not been cleared by the FDA. Organizations seeking information on indication for use or regulatory approval in other countries are encouraged to contact IBEX directly.